DarPharma Inc.
This article was originally published in Start Up
Executive Summary
DarPharma Inc. is targeting the overlooked D1 family of dopamine receptors in its quest to develop novel therapeutics for CNS and psychiatric disorders. The company is leading with two full D1 agonists for Parkinson's disease. Waiting in the wings are D1 receptor agonists for schizophrenia and memory and cognition disorders.